$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Thursday, 20th February at 7:00 am
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the publication of preclinical data desc...

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
UNCY
Share
LOS ALTOS, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the publication of a review on ...

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Tuesday, 7th January at 7:00 am
LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that data from the Company's oxylanthanum carb...

$Unicycive Therapeutics (UNCY.US)$can we just see green for o ce! its been two weeks !!!!!!

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
Tuesday, 17th December at 7:00 am
LOS ALTOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that data from the Company's oxylanthanum carbonate (OLC)...

$Unicycive Therapeutics (UNCY.US)$ Is this starting to come alive?

$Unicycive Therapeutics (UNCY.US)$
H.C. Wainwright raised the firm’s  on Unicycive Therapeutics () to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
Published first on  – the ultimate source for real-time, market-moving breaking financ

$Unicycive Therapeutics (UNCY.US)$
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Positive
FDA acceptance of OLC New Drug Application with PDUFA date set for June 28, 2025
Strong patient preference for OLC: 79% preferred it over prior therapy
Successful completion of UNI-494 Phase 1 trial with positive safety profile
Patent granted for UNI-494 valid until 2040
Cash runway extended into 2026 with $32.3M cash position
Reduced net loss to $4.1M from $4.4...